| Del No | Title | Lead Beneficiary | Del Date |
| D12.1 | H – Requirement No. 1 | FTELE | 31 Jan 2019 |
| D10.1 | Minutes of the Kick-Off Meeting | FTELE | 31 Mar 2019 |
| D11.1 | UPGRADE dissemination plan | FTELE | 31 Mar 2019 |
| D11.2 | Website and intranet portal | FTELE | 31 Mar 2019 |
| D10.2 | Release of the Data Management plan | FTELE | 30 Jun 2019 |
| D1.5 | ISOR mutagenesis | TUD | 31 Dec 2019 |
| D2.1 | Genome retargeted LV integrases | UPF | 31 Dec 2019 |
| D5.1 | LV phagocytosis assay | FTELE | 31 Dec 2019 |
| D11.3 | First report on networking, public engagement and communication activities | FTELE | 31 Dec 2019 |
| D11.8 | Plan for exploitation of results | FTELE | 31 Dec 2019 |
| D12.2 | A – Requirement No. 3 | FTELE | 30 Jun 2020 |
| D12.4 | EPQ – Requirement No. 5 | FTELE | 30 Jun 2020 |
| D12.5 | GEN – Requirement No. 6 | FTELE | 30 Jun 2020 |
| D10.3 | Minutes of the first Annual Meeting | FTELE | 31 Aug 2020 |
| D1.4 | Improved epigenetic editing tools | FTELE | 31 Dec 2020 |
| D12.3 | A – Requirement No. 4 | FTELE | 31 Jan 2021 |
| D10.4 | Minutes of the second Annual Meeting | FTELE | 30 Apr 2021 |
| D1.6 | Nanopore Sequencing | TUD | 30 Jun 2021 |
| D2.3 | Proof-of-concept of HITI in the retina | FTELE | 30 Jun 2021 |
| D2.4 | Proof-of-concept of HITI in the liver | FTELE | 30 Jun 2021 |
| D5.2 | Anti-AAV immunity | UN NANTES | 30 Jun 2021 |
| D5.3 | Phagocytosis-resistant LV in vivo | FTELE | 30 Jun 2021 |
| D5.4 | Pre-existing anti-Cas9 immunity in vitro | UN NANTES | 30 Jun 2021 |
| D11.4 | Second report on networking, public engagement and communication activities | FTELE | 30 Jun 2021 |
| D6.5 | Model of human HSC mobilization/depletion in mice | FTELE | 30 Dec 2021 |
| D10.5 | Minutes of the third Annual Meeting | FTELE | 30 Apr 2022 |
| D1.1 | Improved CRISPR/Cas tools | UNITN | 30 Jun 2022 |
| D2.2 | Site-specific LV insertion | UPF | 30 Jun 2022 |
| D3.2 | Assay to detect off-target activity SSR | TUD | 30 Jun 2022 |
| D3.3 | Assay to detect donor template integration | UPF | 30 Jun |
| D3.4 | Assay to detect chromosomal rearrangements | MGH | 30 Jun 2022 |
| D4.1 | LV with a retargeted tissue tropism | UPF | 30 Jun 2022 |
| D4.2 | Optimized VEsiCas production | UNITN | 30 Jun 2022 |
| D4.3 | AMP based on synthetic carriers | LMU | 30 Jun 2022 |
| D4.4 | AMP based on lipoplexes | LMU | 30 Jun 2022 |
| D5.5 | Tolerogenic strategies for anti-AAV immunity | UN NANTES | 30 Jun 2022 |
| D5.6 | Pre-existing anti-Cas9 immunity in vivo | UN NANTES | 30 Jun 2022 |
| D5.7 | Anti-inflammatory CRISPR/Cas | LMU | 30 Jun 2022 |
| D6.3 | Selection strategy for edited HSPCs | FTELE | 30 Jun 2022 |
| D6.4 | Clonality assessment of edited HSPCs | FTELE | 30 Jun 2022 |
| D7.1 | Editing of the DM1 locus in muscle | VUB | 30 Jun 2022 |
| D9.3 | LV transduction of liver stem cells | FTELE | 30 Jun 2022 |
| D9.4 | Stability of LV transduction | FTELE | 30 Jun 2022 |
| D11.5 | Third report on networking, public engagement and communication activities | FTELE | 30 Jun 2022 |
| D10.6 | Minutes of the fourth Annual Meeting | FTELE | 30 Apr 2023 |
| D1.3 | New procedure to enhance gene editing | UNITN | 30 Apr 2023 |
| D1.7 | SSR characterization | TUD | 30 Jun 2023 |
| D2.5 | Safe-harbor SSR | TUD | 30 Jun 2023 |
| D3.5 | Specificty profile of epigenome editing | FTELE | 30 Jun 2023 |
| D6.2 | Enhanced engraftment and/or self-renewal of edited HSPCs | FTELE | 30 Jun 2023 |
| D7.2 | Silencing of the p16 gene in muscle | UPF | 30 Jun 2023 |
| D7.3 | Reactivation of the Atg5 gene in muscle | UPF | 30 Jun 2023 |
| D8.1 | hRHO reconstitution upon HITI in the retina | FTELE | 30 Jun 2023 |
| D8.2 | Effects of hRHO reconstitution | FTELE | 30 Jun 2023 |
| D8.3 | mRho editing by VEsiCas delivery | UNITN | 30 Jun 2023 |
| D9.1 | HITI in MPS VI mice | FTELE | 30 Jun 2023 |
| D9.2 | HITI in hemophilic mice | VUB | 30 Jun 2023 |
| D9.5 | LDL-R gene transfer | FTELE | 30 Jun 2023 |
| D9.6 | Epigenetic silencing of Pcsk9 | FTELE | 30 Jun 2023 |
| D11.6 | Fourth report on networking, public engagement and communication activities | FTELE | 30 Jun 2023 |
| D1.2 | Novel high-fidelity Cas variants | UNITN | 30 Jun 2024 |
| D1.8 | Mathematical modelling | TUD | 30 Jun 2024 |
| D3.1 | Specificity profile of genome editing tools | MGH | 30 Jun 2024 |
| D4.5 | Non-viral tissue-targeted AMP | LMU | 30 Jun 2024 |
| D5.8 | Tolerogenic strategies for anti-AAV immunity in NHP | UN NANTES | 30 Jun 2024 |
| D5.9 | Tolerogenic strategies for anti-Cas9 immunity | UN NANTES | 30 Jun 2024 |
| D5.10 | Low-immunogenic CRISPR/Cas | LMU | 30 Jun 2024 |
| D6.1 | Improved genome editing protocols in HSPCs | FTELE | 30 Jun 2024 |
| D6.6 | Matched enhancement to biological conditioning strategies | FTELE | 30 Jun 2024 |
| D10.7 | Minutes of the final Meeting | FTELE | 30 Jun 2024 |
| D11.7 | Final report on communication activities | FTELE | 30 Jun 2024 |
| D11.9 | Report on the exploitation of results | FTELE | 30 Jun 2024 |